Prognostic impact of implantable cardioverter defibrillators and associated adverse events in patients with continuous flow left ventricular assist devices.

Implantation of implantable cardioverter defibrillators (ICD) reduces the risk of all-cause mortality in symptomatic heart failure (HF) patients with severe left ventricular (LV) dysfunction. Nevertheless, the prognostic impact of ICD therapy in continuous flow left ventricular assist device (LVAD) recipients remains controversial. 162 consecutive HF patients, who underwent LVAD implantation at our institution between 2010 and 2019, were categorized according to the presence ( Out of 162 consecutive LVAD recipients 79 patients (48.8%) were preoperatively categorized as Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profile ≤2. The prevalence of severe HF symptoms and preoperative use of short-term circulatory support devices (54.4% vs. 13.8%, ICD therapy in LVAD recipients was not associated with a survival benefit or reduced morbidity after LVAD implantation. Conservative ICD-programming seems to be justified to avoid ICD-related complications and "awake shocks" after LVAD implantation.

Informations de copyright

© 2023 Pausch, Mersmann, Bhadra, Barten, Tönnis, Yildirim, Pecha, Reichenspurner and Bernhardt.

Déclaration de conflit d'intérêts

TT declared consulting activity for Medtronic and Boston Scientific, as well as speaker honorarium from Medtronic. YY and SP declared consulting activity for Medtronic and Philips Medical. HR declared travel grants and speaker honoraria from Abbott and Abiomed. AB declared consulting activity for Abiomed, as well as travel grants and speaker honoraria from Abbott and Abiomed.